Abstract

We aimed to demonstrate a single institution experience of treatment of pancreatic ductal carcinoma and to identify the role of radiation therapy. We assessed all patients who were diagnosed with pancreatic ductal carcinoma from January 2011 to December 2017. A total of 342 patients were enrolled. Thirteen, 131, 36, and 162 patients had stage I, II, III, and IV disease, respectively (UICC TNM, 7th edition). Among the patients with stages I–III disease, 94 underwent surgery, and the median overall survival (OS) was 33 months. Of patients with stages I–III disease who were not suitable for surgery, 58 patients received chemotherapy, and the median OS was 12 months. Among them, 17 patients received chemoradiotherapy added on chemotherapy and their OS was significantly better than that of patients who received chemotherapy alone. Of patients with stage IV disease who were not suitable for surgery, 58 patients received chemotherapy, and the median OS was 6 months. This study evaluated the demand, role, and outcome of each treatment modality and demonstrated a single institution experience of treatment of pancreatic ductal carcinoma. The demand and role of radiation therapy remained small; however, radiation therapy might have some importance as a local treatment.

Introduction

Pancreatic cancer is the fourth leading cause of cancer-related mortality in Japan. Its prognosis remains poor, and an estimated 34,200 deaths occurred in Japan in 2017 [1]. The high biologically malignant nature of pancreatic cancer facilitates infiltration into the surrounding tissues and distant metastasis. Surgical resection is a treatment with the potential for cure; however, only <20% of all patients with pancreatic cancer are diagnosed with resectable disease [2].
Therefore, for unresectable tumors that account for the majority of pancreatic cancer cases, other treatment modalities, such as radiation therapy and chemotherapy, are also important. Various studies about the treatment depending on the status of patient’s disease (resectable, borderline resectable, unresectable tumors, and metastatic disease) have been reported. However, in Japan, no previous study has reported on the prevailing status of pancreatic cancer treatment, such as a nationwide survey. Therefore, it is difficult to understand the actual status of the treatment for this disease.

In this study, we analyzed all pancreatic cancer cases at a single institution based on their treatment, such as surgery, radiation therapy, chemotherapy, and palliative therapy. We aimed to identify the demand, role, and outcome of each treatment modality and demonstrate a single institution experience of treatment of pancreatic ductal carcinoma to understand the actual status. In particular, we focused on the demand and role of radiation therapy.

Materials and methods

Patients

From January 2011 to December 2017, 428 patients with pancreatic tumor were diagnosed at Hiroshima Prefectural Hospital. Among these patients, those who were pathologically or clinically diagnosed with pancreatic ductal carcinoma were included in the analysis. We did not exclude patients without a pathological diagnosis as the advancements in radiographic studies and tumor markers improved the accuracy of the clinical diagnosis, and undergoing invasive diagnostic procedures was sometimes a burden for these patients, such as those undergoing palliative treatment. We thought that the investigation including such cases was important to understand the actual state of pancreatic cancer treatment in clinical practice. Patients with pancreatic intraepithelial neoplasia, neuroendocrine carcinoma, intraductal papillary mucinous neoplasm, acinar cell carcinoma, squamous cell carcinoma, and cystadenocarcinoma were excluded. Patients whose clinical findings before treatment or the details of treatment were insufficient or those who were lost to follow-up immediately after diagnosis or treatment were also excluded.

Before therapy, all patients underwent clinical evaluation by assessment of previous medical history, physical and laboratory examinations, and radiographic studies. Most of the patients underwent endoscopic ultrasound-guided fine needle aspiration. The following laboratory examinations were performed: complete blood cell count, liver function studies, renal function studies, measurement of electrolytes, and carbohydrate antigen 19–9 assay. The following radiographic studies were performed: computed tomography of the chest, abdomen, and pelvis and magnetic resonance imaging of the liver if liver metastasis had been suspected. The clinical TNM stage was defined according to the Union for International Cancer Control tumor node metastasis classification system, 7th edition. The study protocol was approved by the Human Ethics Review Committee of Hiroshima Prefectural Hospital. The need for informed consent was waived due to the retrospective nature of this study.

Treatment

Among patients with stages I–III disease, those with operable pancreatic cancer underwent surgery. Postoperatively, most of the patients underwent adjuvant chemotherapy. Depending on the case, postoperative radiation therapy was performed when the surgical margin was positive. Patients with borderline resectable or unresectable pancreatic cancer underwent chemotherapy. Patients in whom the tumor had shrunk after chemotherapy and had been judged to be operable underwent surgery. Chemoradiotherapy (CRT) was considered when the tumor was not suitable for surgery after several cycles of chemotherapy, but the lesions were localized.
The patients who were not suitable for both surgery and chemotherapy due to their general condition or coexisting diseases received palliative therapy only. Patients with stage IV disease received chemotherapy, while those for whom chemotherapy was not suitable received palliative therapy.

Evaluation and statistical analysis

We analyzed the overall survival (OS) rate of the entire cohort, those of patients with various stages, and that for each treatment modality. Among patients with stages I–III disease, those who underwent surgery were categorized as the surgery group, and those who received chemotherapy without surgery as the chemotherapy group. In the chemotherapy group, we compared the OS rates of patients with CRT with that of those without CRT. CRT added on chemotherapy was administered only in patients without distant metastasis after several cycles of chemotherapy (median duration, 4 months). To avoid selection bias, among patients who received chemotherapy alone, those who died or developed distant metastasis within 4 months after the first treatment were excluded from this comparison. In addition, univariate analyses using the Mantel–Haenszel \( \chi^2 \)-test and multivariate analyses using logistic regression were performed to determine the statistical significance of differences in OS. Investigated factors included age, sex, performance status, tumor location, TNM stage, CA19-9 level, and presence of CRT.

The Kaplan–Meier method was used to calculate the OS rate. The OS was calculated from the date of initiation of the first treatment until the date of the final follow-up or death of any cause. The \( \chi^2 \) test or Student’s \( t \)-test was conducted to determine the significant differences between surgery group and chemotherapy group and between the patients who received CRT added on chemotherapy and those who received chemotherapy alone. Ekuseru-Toukei 2015 (version 1.02; Social Survey Research Information Co., Ltd., Tokyo, Japan) was used to perform the statistical analyses. Analysis items with \( p < 0.05 \) were considered statistically significant.

Results

Patients

Of the 428 patients who were diagnosed with pancreatic tumor at Hiroshima Prefectural Hospital, 86 were excluded from the analysis. Forty-nine patients were excluded due to their pathological diagnoses, 33 were excluded due to insufficient data on treatments, and 4 were lost to follow-up immediately after diagnosis or treatment. Therefore, 342 patients were finally enrolled in this study. The characteristics of the eligible patients are summarized in Table 1. The median age of the patients was 73 (range, 47–97) years and 51.8% of the patients were men. Two hundred and fifty-seven (75.1%) patients were diagnosed pathologically, while 85 (24.9%) were diagnosed clinically with invasive ductal carcinoma of the pancreas. One hundred and seventy-one (50.0%) patients had tumors in the head, 95 (27.8%) had tumors in the body, and 76 (22.2%) had tumors in the tail of the pancreas. Moreover, 10 (2.9%), 9 (2.6%), 215 (62.9%), and 108 (31.6%) patients developed T1, T2, T3, and T4 disease, respectively. Meanwhile, 146 (42.7%) patients had regional lymph node metastases. Thirteen (3.8%), 131 (38.3%), 36 (10.5%), and 162 (47.4%) patients had stage I, II, III, and IV disease, respectively. The median follow-up periods at the time of evaluation were 9 (range, 0–94) months in all patients and 25 (range, 5–94) months among survivors.

Ninety-four (27.5%) patients underwent surgery. Among them, 82 patients received neoadjuvant and/or adjuvant chemotherapy. Meanwhile, 251 (73.4%) patients underwent chemotherapy. Except for those who received palliative therapy only, 95.4% of patients received...
chemotherapy. Forty-four (12.9%) patients received radiation therapy. Among them, pre/post-operative radiation therapy was administered to 5 patients, CRT added on chemotherapy for local control was administered to 17 patients, and radiation therapy for recurrence or metastasis was administered to 22 patients. Seventy-nine (23.1%) patients received palliative therapy only.

### Outcomes of all patients

Fig 1 shows the OS rates of the entire patient cohort and those with various stages of pancreatic cancer. The median OS of all patients was 9 (95% confidence interval [CI], 7.8–10.2) months.

### Table 1. Patient characteristics.

|                  | Total |
|------------------|-------|
|                  | n = 342 | 100 (%) |
| Age, years, median (range) | 73 (47–97) | - |
| Sex              |       |
| Male             | 177    | 51.8 |
| Female           | 165    | 48.2 |
| Pathological diagnosis |       |
| Available        | 257    | 75.1 |
| Not available    | 85     | 24.9 |
| Location         |       |
| Head             | 171    | 50.0 |
| Body             | 95     | 27.8 |
| Tail             | 76     | 22.2 |
| Stage            |       |
| I                | 13     | 3.8  |
| II               | 131    | 38.3 |
| III              | 36     | 10.5 |
| IV               | 162    | 47.4 |
| T stage          |       |
| T1               | 10     | 2.9  |
| T2               | 9      | 2.6  |
| T3               | 215    | 62.9 |
| T4               | 108    | 31.6 |
| N stage          |       |
| N0               | 196    | 57.3 |
| N1               | 146    | 42.7 |
| CA19-9, U/ml, median (range) | 245 (1–921500) | - |
| Surgery          |       |
| Yes              | 94     | 27.5 |
| RT               |       |
| Yes              | 44     | 12.9 |
| (CRT added on chemotherapy) | 17 |
| (Pre/postoperative RT) | 5 |
| (RT for recurrence or metastasis) | 22 |
| Chemotherapy     |       |
| Yes              | 251    | 73.4 |
| (Neoadjuvant/adjuvant) | 82 |
| (Without surgery) | 169 |
| Palliative therapy alone | Yes | 79 | 23.1 |

RT, radiation therapy; CRT, chemoradiotherapy; CA19-9, carbohydrate antigen 19–9

[https://doi.org/10.1371/journal.pone.0227305.t001](https://doi.org/10.1371/journal.pone.0227305.t001)
The 3-year OS rate was 16.0% (95% CI, 11.5–20.5). The 3-year OS rates of patients with stage I, II, III, and IV disease were 69.2% (95% CI, 44.1–94.3), 29.0% (95% CI, 20.2–37.8), 9.5% (95% CI, 0–21.3), and 0% (95% CI, 0–0), respectively. During the follow-up period, 276 (80.7%) patients died; among these, 273 died of pancreatic cancer and only 3 died of other diseases.

Stages I–III pancreatic cancer

Surgery group. The characteristics of the surgery group are summarized in Table 2. The median age was 73 (range, 47–88) years. Among them, 9 (9.6%), 83 (88.3%), and 2 (2.1%) patients had stages I, II, and III disease, respectively. Sixty-two patients underwent pancreatoduodenectomy, while 32 underwent distal pancreatectomy. Neoadjuvant chemotherapy was administered to 6 patients, and adjuvant chemotherapy to 80 patients. Among them, 5 patients underwent pre- or postoperative radiation therapy. The median OS period was 33 (95% CI, 22.3–43.7) months, and the 3-year OS rate was 44.0% (95% CI, 32.5–55.6) (Fig 2). In the surgery group, 44 (46.8%) patients were still alive at the time of evaluation and 12 (12.8%) survived for more than 5 years.

Table 2. Characteristics of patients from the surgery and chemotherapy groups.

| Pathological diagnosis | Surgery group | Chemotherapy group | P value |
|------------------------|--------------|--------------------|---------|
| Available              | 94 (100)     | 47 (81)            | <0.0001 |
| Not available          | 0 (0)        | 11 (19)            | 0.4720  |
| Location               |              |                    |         |
| Head                   | 59 (62.8)    | 33 (56.9)          |         |
| Body                   | 26 (27.7)    | 21 (36.2)          |         |
| Tail                   | 9 (9.6)      | 4 (6.9)            |         |
| Stage                  |              |                    | <0.0001 |
| I                      | 9 (9.6)      | 1 (1.7)            |         |
| II                     | 83 (88.3)    | 29 (50.0)          |         |
| III                    | 2 (2.1)      | 28 (48.3)          |         |
| T stage                |              |                    | <0.0001 |
| T1                     | 7 (7.4)      | 1 (1.7)            |         |
| T2                     | 4 (4.3)      | 0 (0)              |         |
| T3                     | 81 (86.2)    | 29 (50.0)          |         |
| T4                     | 2 (2.1)      | 28 (48.3)          |         |
| N stage                |              |                    | 0.2068  |
| N0                     | 72 (76.6)    | 39 (67.2)          |         |
| N1                     | 22 (23.4)    | 19 (32.8)          |         |
| CA19-9, U/ml, median (range) | 95.5 (1–7454) | 219.5 (1–68811) | 0.0988  |

CA19-9, carbohydrate antigen 19–9

https://doi.org/10.1371/journal.pone.0227305.t002
Chemotherapy group. Among patients with stages I–III disease, 86 were not suitable for surgery. Among them, 28 patients received palliative therapy only, and the other 58 patients received chemotherapy. The characteristics of the chemotherapy group are summarized in Table 2. The median age of the chemotherapy group was 71 (range, 47–97) years. Among them, 1 (1.7%), 29 (50.0%), and 28 (48.3%) patients had stages I, II, and III disease, respectively. The medications administered as initial treatment were gemcitabine in 23 patients, gemcitabine plus S-1 in 5 patients, gemcitabine plus nanoparticle albumin-bound (nab)-paclitaxel in 9 patients, FOLFIRINOX (combination chemotherapy regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin) in 13 patients, and others in 8 patients, respectively. In the chemotherapy group, the median OS was 12 months (95% CI, 8.9–15.1), and the 3-year OS rate was 15.7% (95% CI, 4.8–26.5) (Fig 2).

In the chemotherapy group, 17 patients received CRT added on chemotherapy. Three-dimensional conformal radiation therapy was used for treatment planning. Primary tumors and lymph node metastases with adequate margins were irradiated. The total prescribed dose was 50.4 Gy using 6–10 MV photon beams (1.8 Gy/fraction). Only 3 patients received proton beam therapy. The prescribed dose was 67.5 GyE (gray equivalent) using proton beams (2.7 GyE/fraction). The median duration from initial chemotherapy to CRT was 4 (range, 0–11) months. All patients received concurrent chemotherapy. S-1 was administered to 11 patients and gemcitabine to 6 patients. Fig 3 shows a comparison of the OS between the patients who
received CRT added on chemotherapy and those who received chemotherapy alone. No significant differences in patient or tumor characteristics were observed between groups, except in terms of age (Table 3). The median OS of the patients who received CRT added on chemotherapy was significantly better than that of patients who received chemotherapy alone (25 vs 11 months, p = 0.0320). Table 4 shows the univariate and multivariate analyses of OS. Performance status (0 or 1) and CRT added on chemotherapy were significant prognostic factors of OS in the univariate analysis and performance status (0 or 1) remained significant in the multivariate analysis (p = 0.0125). The patients who received CRT added on chemotherapy tended to have good prognoses; however, CRT added on chemotherapy was not significant in the multivariate analysis (p = 0.0751).

**Stage IV pancreatic cancer**

Of the 162 patients who had stage IV disease, 111 received chemotherapy. The medications administered as initial treatment were gemcitabine in 61 patients, gemcitabine plus S-1 in 9 patients, gemcitabine plus nab-paclitaxel in 17 patients, FOLFIRINOX in 13 patients, and others in 11 patients, respectively. Fifty-one patients received palliative therapy only. Fig 4 shows
the OS of the patients with stage IV disease who received chemotherapy and those who received palliative therapy only. The median OS periods of the patients who received chemotherapy and those who received palliative therapy only were 6 months (95% CI, 4.4–7.6) and 1 month (95% CI, 0.7–1.3), respectively.

Discussion
Pancreatic cancer is considered a life-threatening disease and has a high distant metastasis rate of 40–45% at diagnosis [3]. About half of the patients in this study had metastatic disease. Only 3.8% of patients had stage I disease, 38.3% had stage II disease, and 10.5% had stage III disease. About half of patients with stages I–III disease underwent surgery, 30% received chemotherapy without surgery, and 20% received palliative therapy only. In the chemotherapy group, 30% of the patients received CRT added on chemotherapy. Approximately 70% of patients with stage IV disease received chemotherapy, and 30% received palliative therapy only. Of the entire patient cohort, about 30% underwent surgery, about half received chemotherapy without surgery, and 20% received palliative therapy only. Only 5% of the entire patient cohort received CRT added on chemotherapy for local control.
Although surgery is generally a small part of the entire pancreatic cancer treatment, the proportion of patients who underwent surgery in this study was relatively high compared with that reported in other studies [2, 3]. The advancements in diagnostic studies and the current status of new chemotherapy regimens might have contributed to this result. In addition, at our institution, we discuss the treatment of each pancreatic cancer patient on the cancer board, and the relatively high number of patients who underwent surgery might be the result of appropriate case assignment. The outcomes of patients who underwent surgery were relatively good. The 3-year OS rate was 44.0%, and 12 patients survived for more than 5 years. Certainly, most patients in the surgery group had stage I or II disease, and their general conditions were relatively good, but surgery was a potentially curative treatment for those patients.

The demand for chemotherapy in the treatment of all stages of pancreatic cancer was extremely high. In this study, 95.4% of patients received chemotherapy, except for those who received palliative therapy only. The role of chemotherapy is important in various situations: in patients with metastatic disease, in patients who require adjuvant therapy, and in patients who require a combination of radiation and chemotherapy. However, the treatment outcome of patients with stages I–III disease who received chemotherapy without surgery was poorer than that of patients who underwent surgery, and chemotherapy was not a curative treatment. Of course, it had to be taken into consideration that the chemotherapy group had more advanced cases. In addition, combination chemotherapy regimens, such as FOLFIRINOX and nab-paclitaxel plus gemcitabine, were shown to be effective for metastatic pancreatic cancer and were recommended in Japan in 2016 [4–7]; however, in this study, the proportion of new regimens was small due to their novelty. Therefore, the use of these regimens is expected to increase and the treatment outcome of chemotherapy for pancreatic cancer will further improve in the future.

Among patients who received chemotherapy alone, those who died or developed distant metastasis 4 months after the first treatment were excluded from these analyses. OS, overall survival; UVA, univariate analysis; MVA, multivariate analysis; CI, confidence interval; CA19-9, carbohydrate antigen 19–9; CRT, chemoradiotherapy

---

Table 4. Prognostic factors in the chemotherapy group; univariate and multivariate analysis.

|                        | Median OS (month) | UVA P value | MVA P value | Hazard ratio (95% CI) |
|------------------------|------------------|-------------|-------------|----------------------|
| Age, years             |                  |             |             |                      |
| < 70                   | 19               | 0.0582      | -           | -                    |
| ≥ 70                   | 11               | -           | -           | -                    |
| Sex                    |                  |             |             |                      |
| Male                   | 18               | 0.3395      | -           | -                    |
| Female                 | 13               | -           | -           | -                    |
| Performance status     |                  |             |             |                      |
| 0 or 1                 | 19               | 0.0019      | 0.0125      | 0.28 (0.11–0.76)     |
| 2                      | 9                | -           | -           | -                    |
| Location               |                  |             |             |                      |
| Head                   | 12               | 0.9435      | -           | -                    |
| Body or Tail           | 18               | -           | -           | -                    |
| Stage                  |                  |             |             |                      |
| II                     | 12               | 0.9815      | -           | -                    |
| III                    | 19               | -           | -           | -                    |
| T stage                |                  |             |             |                      |
| 3                      | 12               | 0.9815      | -           | -                    |
| 4                      | 19               | -           | -           | -                    |
| N stage                |                  |             |             |                      |
| 0                      | 19               | 0.1540      | -           | -                    |
| 1                      | 11               | -           | -           | -                    |
| CA19-9, U/ml           |                  |             |             |                      |
| < 250                  | 19               | 0.2020      | -           | -                    |
| ≥ 250                  | 12               | -           | -           | -                    |
| Presence of CRT        |                  |             |             |                      |
| Yes                    | 25               | 0.0320      | 0.0751      | 0.53 (0.26–1.07)     |
| No                     | 11               | -           | -           | -                    |

Among patients who received chemotherapy alone, those who died or developed distant metastasis 4 months after the first treatment were excluded from these analyses. OS, overall survival; UVA, univariate analysis; MVA, multivariate analysis; CI, confidence interval; CA19-9, carbohydrate antigen 19–9; CRT, chemoradiotherapy

https://doi.org/10.1371/journal.pone.0227305.t004
In patients with stages I–III disease, who were not suitable for surgery, the demand of CRT for local control was small. In addition, CRT added on chemotherapy was significant in the univariate analysis, but was not significant in the multivariate analysis. However, we presume that CRT added on chemotherapy had some advantages. The reason was that the OS of the patients who received CRT added on chemotherapy was better than that of those who received chemotherapy alone. We excluded the patients who immediately died or developed metastatic disease after receiving the first few cycles of systemic chemotherapy from this comparison to avoid selection bias. In addition, there were no significant differences between patient and tumor factors in the two groups, except for age. CRT added on chemotherapy was not significant in the multivariate analysis, but the patients who received CRT added on chemotherapy tended to have a good prognosis, and we thought there would have been some positive effect. On the other hand, radiation therapy could not be considered as curative treatment as it was difficult to administer a high radiation dose in three-dimensional conformal radiation therapy due to the anatomical location of the pancreas, and none of the patients who received CRT survived for more than 5 years in this study. The effectiveness of CRT following chemotherapy

Fig 4. Overall survival (OS) of patients with stage IV disease who received chemotherapy and those who received palliative therapy. The median OS periods of patients with stage IV disease who received chemotherapy and those who received palliative therapy were 6 months and 1 month, respectively.

https://doi.org/10.1371/journal.pone.0227305.g004
had been reported in several studies, but treatment results were not satisfactory and the median OS ranged from 11.9 to 18.7 months [8–14]. Recently, several studies reported the new radiation techniques for pancreatic cancer, such as intensity-modulated radiation therapy, stereotactic body radiation therapy, and particle radiation therapy [15–19]. In the future, these techniques might be considered as curative treatments.

In addition, we refer to radiation therapy as a part of the multidisciplinary treatment. Among the patients treated with radiation therapy in this study, 5 who underwent radiation therapy before or after surgery survived for a long time (median, 79 months). The subsets of patients, such as those with positive surgical margins, may be more likely to benefit from adjuvant CRT [8, 20]. The effectiveness of neoadjuvant CRT for borderline resectable pancreatic cancer has been reported in several studies. However, certain factors remained controversial, such as eligible criteria and results of the comparison between neoadjuvant CRT and neoadjuvant chemotherapy [21–23]. In this study, neoadjuvant CRT was given in only one patient whose tumor decreased in size after CRT and became resectable. These approaches required enough discussion; besides, the role of radiation therapy as a part of the multidisciplinary treatment seemed to be important.

This study reported on the demand, role, and outcome of each treatment modality for pancreatic cancer in a single institution. Although it was retrospective in nature and used a small sample size, this study was meaningful in reporting pancreatic cancer treatment. The role of surgery as potentially curative treatment and the high demand of chemotherapy as treatment for pancreatic cancer were confirmed in this study. The demand and role of radiation therapy in the treatment of all stages of pancreatic cancer remained small in actual clinical practice; however, radiation therapy might have some importance as a local treatment depending on the status of the patient.

Author Contributions

Investigation: Katsumaro Kubo.
Methodology: Koichi Wadasaki.
Project administration: Katsumaro Kubo.
Writing – original draft: Katsumaro Kubo.
Writing – review & editing: Koichi Wadasaki, Daisuke Komichi, Tamito Sasaki, Hiroyasu Yamada, Yasuhiro Matsugu, Toshiyuki Itamoto, Mihoko Doi, Katsunori Shinozaki.

References

1. National Cancer Center, Center for Cancer Control and Information Services. Latest cancer statistics 2017. Available from URL: http://ganjoho.jp/reg_stat/statistics/stat/summary.html.
2. Sen N, Falk S, Abrams R. Role of chemoradiotherapy in the adjuvant and neoadjuvant settings for resectable pancreatic cancer. Clin Oncol. 2014; 26: 551–559.
3. Palta M, Willet CG, Czito BG. Pancreatic cancer. In: Halperin EC, Wazer DE, Perez CA, Brady LW, editors: Principles and practice of radiation oncology. 6th ed, Philadelphia: Lippincott Williams & Wilkins: 1189–1202.
4. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus Gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364: 1817–1825. https://doi.org/10.1056/NEJMoa1011923 PMID: 21561347
5. Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, Ychou M, Bouche O, Guimbaud R, et al. Impact of FOLFIRINOX compared with Gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol. 2013; 31: 23–29. https://doi.org/10.1200/JCO.2012.44.4869 PMID: 23213101
6. Tabernero J, Chiorean EG, Infante JR, Hingorani SR, Ganju V, Weekes C, et al. Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-Paclitaxel plus Gemcitabine versus Gemcitabine alone in patients with metastatic pancreatic cancer. Oncologist. 2015; 20: 143–150. https://doi.org/10.1634/theoncologist.2014-0394 PMID: 25582141

7. Yamaguchi K, Okusaka T, Shimizu K, Furuse J, Ito Y, Hanada K, et al. Clinical Practice Guidelines for Pancreatic Cancer 2016 From the Japan Pancreas Society: A Synopsis. Pancreas. 2017; 46: 595–604. https://doi.org/10.1097/MPA.0000000000000816 PMID: 26426492

8. National Comprehensive Cancer Network Inc NCCN Clinical Practice Guidelines in Oncology. Pancreatic Adenocarcinoma version 2. 2018. Available from URL: https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#pancreatic.

9. Krishnan S, Rana V, Janjan NA, Varadadhary GR, Abbruzzese JL, Das P, et al. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidation chemoradiation therapy. Cancer. 2007; 110: 47–55. https://doi.org/10.1002/cncr.22735 PMID: 17538975

10. Huguet F, Andre T, Hammel P, Artru P, Balosso J, Selle F, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol. 2007; 25: 326–331. https://doi.org/10.1200/JCO.2006.07.5663 PMID: 17235048

11. Arvold ND, Ryan DP, Niemierko A, Blaszkowsky LS, Kwak EL, Wo JY, et al. Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer. Cancer. 2012; 118: 3026–3035. https://doi.org/10.1002/cncr.26633 PMID: 22020923

12. Leone F, Gatti M, Massucco P, Colombi F, Speri E, Campanella D, et al. Induction Gemcitabine and Oxaliplatin therapy followed by a twice-weekly infusion of Gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced adenocarcinoma pancreatic cancer. Cancer. 2013; 119: 277–284. https://doi.org/10.1002/cncr.227736 PMID: 22778019

13. Esnaola NF, Chaudhary UB, O’Brien P, Garrett-Mayer E, Camp ER, Thomas MB, et al. Phase 2 trial of induction Gemcitabine, Oxaliplatin, and Cetuximab followed by selective Capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2014; 88: 837–844. https://doi.org/10.1016/j.ijrobp.2013.12.030 PMID: 24606850

14. Krishnan S, Chadha AS, Suh Y, Chen HC, Rao A, Das P, et al. Focal radiation therapy dose escalation improves overall survival in locally advanced pancreatic cancer patients receiving induction chemotherapy and consolidative chemoradiation. Int J Radiat Oncol Biol Phys. 2015; 94: 755–765. https://doi.org/10.1016/j.ijrobp.2015.12.003 PMID: 26972648

15. Yovino S, Poppe M, Jabbour S, David V, Garofalo M, Pandya N, et al. Intensity-modulated radiation therapy significantly improves acute gastrointestinal toxicity in pancreatic and ampullary cancers. Int J Radiat Oncol Biol Phys. 2011; 79: 158–162. https://doi.org/10.1016/j.ijrobp.2010.04.035 PMID: 20399035

16. Abelson JA, Murphy JD, Minn AY, Chung M, Fisher GA, Ford JM, et al. Intensity-modulated radiotherapy for pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys. 2012; 82: 595–601.

17. de Geus SWL, Eskander MF, Kasumova GG, Ng SC, Kent TS, James Moser A, et al. Stereotactic body radiotherapy for unresectable pancreatic cancer: a nationwide review. Cancer. 2017; 123: 4158–4167. https://doi.org/10.1002/cncr.30856 PMID: 28708929

18. Zhu X, Ju X, Cao Y, Shen Y, Cao F, Qing S, et al. Patterns of local failure after stereotactic body radiation therapy and sequential chemotheraphy as initial treatment for pancreatic cancer: implications of target volume design. Int J Radiat Oncol Biol Phys. 2019; 104: 101–110. https://doi.org/10.1016/j.ijrobp.2019.01.075 PMID: 3068663

19. Jethwa KR, Tryggestad EJ, Whitaker TJ, Giffey BT, Kazemba BD, Neben-Wittich MA, et al. Initial experience with intensity modulated proton therapy for intact, clinically localized pancreas cancer: Clinical implementation, dosimetric analysis, acute treatment-related adverse events, and patient-reported outcomes. Adv Radiat Oncol. 2018; 3: 314–321. https://doi.org/10.1016/j.radonc.2018.04.003 PMID: 30202800

20. Butturini G, Stocken DD, Wente MN, Jeekel H, Kinkebiril JJ, Bakkevold KE, et al. Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. Arch Surg. 2008; 143: 75–83. https://doi.org/10.1001/archsurg.2007.17 PMID: 18209156

21. Katz MHG, Shi Q, Ahmad SA, Herman JM, Marsh Rbe W, Collisson E, et al. Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: alliance for clinical trials in oncology trial A021101. JAMA Surg. 2016; 151: e161137. https://doi.org/10.1001/jamasurg.2016.1137 PMID: 27275632
22. Mellon EA, Hoffe SE, Springett GM, Frakes JM, Strom TJ, Hodul PJ, et al. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Acta Oncol. 2015; 54: 979–985. https://doi.org/10.3109/0284186X.2015.1004367 PMID: 25734581

23. Katz MHG, Ou FS, Herman JM, Ahmad SA, Wolpin B, Marsh R, et al. Alliance for clinical oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas. BMC Cancer. 2017; 17:505. https://doi.org/10.1186/s12885-017-3441-z PMID: 28750659